WindMIL Therapeutics

About

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients.

Princeton,New Jersey,United States
11 - 50

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $32.50M
Industries: Biotechnology,Medical Device,Therapeutics
Founded date: Jan 1, 2015
Number Of Employee: 11 - 50
Operating Status: Active
Legal Name: WindMIL Therapeutics, Inc.

WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.

WindMIL Therapeutics was established in 2015 and is based in Baltimore, MD.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

2

$42.50M

WindMIL Therapeutics has raised a total of $42.50M in funding over 2 rounds. Their latest funding was raised on Jun 18, 2018 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jun 18, 2018	Series B	$32.50M	5	Qiming Venture Partners	—	Detail
Apr 7, 2016	Series A	$10M	1	Scott H. Cohen	—	Detail

Investors

Number of Lead Investors

Number of Investors

2

6

WindMIL Therapeutics is funded by 6 investors. Qiming Venture Partners and Scott H. Cohen are the most recent investors.

Investor Name	Lead Investor	Funding Round
Qiming Venture Partners	Yes	Series B
Scott H. Cohen	Yes	Series A
Medivate Partners	—	Series B
Camden Partners	—	Series B
Domain Associates	—	Series B
FoxKiser	—	Series B